Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Más filtros










Base de datos
Intervalo de año de publicación
1.
Pharmacol Rep ; 75(3): 715-725, 2023 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-37017868

RESUMEN

BACKGROUND: COVID-19 has been challenging for the entire healthcare system, due to the lack of sufficient treatment protocols, especially during initial phases and as regards antibiotic use. The aim of this study was to identify the trends of antimicrobial consumption in one of the largest tertiary hospitals in Poland during COVID-19. METHODS: This is a retrospective study conducted at the University Hospital in Krakow, Poland, between Feb/Mar 2020 and Feb 2021. It included 250 patients. All included patients were hospitalized due to COVID-19 with confirmed SARS-CoV-2 infection without bacterial co-infections during the first phase of COVID-19 in Europe and following 3-month intervals: five equal groups of patients in each. COVID severity and antibiotic consumption were assessed according to WHO recommendations. RESULTS: In total 178 (71.2%) patients received antibiotics with a incidence rate of laboratory-confirmed healthcare-associated infection (LC-HAI) was 20%. The severity of COVID-19 was mild in 40.8%, moderate in 36.8%, and severe in 22.4% cases. The ABX administration was significantly higher for intensive care unit (ICU) patients (97.7% vs. 65.7%). Length of hospital stay was extended for patients with ABX (22.3 vs. 14.4 days). In total, 3 946.87 DDDs of ABXs were used, including 1512.63 DDDs in ICU, accounting for 780.94 and 2522.73 per 1000 hospital days, respectively. The median values of antibiotic DDD were greater among patients with severe COVID-19 than others (20.92). Patients admitted at the beginning of the pandemic (Feb/Mar, May 2020) had significantly greater values of median DDDs, respectively, 25.3 and 16.0 compared to those admitted in later (Aug, Nov 2020; Feb 2021), respectively, 11.0, 11.0 and 11.2, but the proportion of patients receiving ABX therapy was lower in Feb/Mar and May 2020 (62.0 and 48.0%), whereas the highest during the late period of the pandemic, i.e., in Aug, Nov. 2020 and Feb. 2021 (78% and both 84.0%). CONCLUSIONS: Data suggest great misuse of antibiotics without relevant data about HAIs. Almost all ICU patients received some antibiotics, which was correlated with prolonged hospitalization.


Asunto(s)
COVID-19 , Humanos , COVID-19/epidemiología , Estudios Retrospectivos , Pandemias , SARS-CoV-2 , Polonia/epidemiología , Antibacterianos/uso terapéutico , Análisis de Series de Tiempo Interrumpido , Hospitales
2.
Med Pr ; 72(6): 721-728, 2021 Dec 22.
Artículo en Polaco | MEDLINE | ID: mdl-34931085

RESUMEN

Intensive care units are characterized by the high risk of infections in patients. Pneumonia is one of the most common forms of infection with a high risk of death. Hence, to improve patient safety, specific packages of procedures, the so-called "bundle care," are recommended by experts in the field. The usage of selected protective procedures carries the risk of transmitting microbes from patients to staff, which in the case of pathogens such as SARS-CoV-2 can have serious health consequences for staff. Therefore, medical staff of intensive care units should strictly follow recommendation concerning healthcare workers safety and the rules of isolation, which in the current pandemic should be supplemented with specific elements. The paper presents an overview of the optimization of patient care and staff safety within the so-called "bundle care" in the COVID-19 pandemic. Med Pr. 2021;72(6):721-8.


Asunto(s)
COVID-19 , Pandemias , Personal de Salud , Humanos , Respiración Artificial/efectos adversos , SARS-CoV-2
3.
Antimicrob Resist Infect Control ; 10(1): 154, 2021 10 26.
Artículo en Inglés | MEDLINE | ID: mdl-34702342

RESUMEN

INTRODUCTION: The aim of this research study was to compare the situation concerning the use of microbiology testing, the epidemiology of healthcare-associated infection (HAI) and antimicrobial consumption (AMC) in Polish long-term care facilities (LTCFs) with other European countries, using the most recent findings available in the European databases. Furthermore, this study aimed to highlight several basic factors that contribute to the observable differences in AMC between countries participating in the HALT-3 study, especially the relationship with demographic indicators, as well as the health care resources utilization rates. PATIENTS AND METHODS: The most recent HAIs in Long-Term care facilities Point Prevalence Survey (HALT PPS) was carried out in EU/EEA countries in 2016-2017, and in Poland it was carried out in April-June 2017 in 24 LTCFs. AMC data was collected with use of methodology of the Anatomical Therapeutic Chemical (ATC) classification system of the WHO. RESULTS: In total total in HALT-3 study on the day of the PPS, 5035 out of the 102,301 eligible residents received at least one antimicrobial agent, with prevalence of 4.9%, and in Poland 3.2%. The most common HAIs in the countries included into the study was urinary tract infection with relative frequency of 32%, in Poland it was skin infection, 30.4%. The respiratory tract infections, excluding pneumonia (PNU) were observed in 29.5% of residents in total, in Poland 17.4%, the prevalence rate of PNU were 1.4% and 5.4%, respectively. The lack of microbiological results of HAIs testing concerned the vast majority of all HAIs, 75.8% in total and 81.5% in Poland. The most frequently used antibacterial for systemic use were beta-lactams and the most frequently prescribed antimicrobial agent was 'amoxicillin and enzyme inhibitor'. AMC was closely correlated with the age of the general population (65 years of age and more) and the availability of doctors in general population. CONCLUSIONS: A significant problem observed in LTCFs was the empirical use of antibiotics and the scarcity of microbiological testing. In the studied Polish LTCFs, where the age of residents was low, also the AMC was found to be lower.


Asunto(s)
Antibacterianos/administración & dosificación , Cuidados a Largo Plazo , Anciano , Antibacterianos/clasificación , Europa (Continente) , Humanos , Polonia
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...